SELLAS Life Sciences (SLS) Capital Expenditures (2010 - 2016)
SELLAS Life Sciences (SLS) posted quarterly Capital Expenditures of -$6000.0 for Q4 2016, down 101.32% year-over-year from $453000.0 in Q1 2016, and down 200.0% quarter-over-quarter from $6000.0 in Q1 2016.
Powered by 
Analysis
SELLAS Life Sciences (SLS) Capital Expenditures (2010 - 2016) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Capital Expenditures for 6 consecutive years, with -$6000.0 the latest figure, recorded in Q4 2016.
- In Q4 2016, Capital Expenditures fell 101.32% year-over-year to -$6000.0; the TTM figure through Sep 2016 stood at $459000.0 (up 410.0% YoY), while the FY2015 annual figure was $534000.0, up 836.84% from the prior year.
- Capital Expenditures retreated to -$6000.0 in Q4 2016 per SLS's latest filing, from $6000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $500000.0 in Q1 2015 and bottomed at -$466000.0 in Q2 2015.
- Historically, Capital Expenditures has averaged $38416.7 across 4 years, with a median of $14000.0 in 2014.
- On a YoY basis, Capital Expenditures climbed as much as 4933.33% in 2015 and fell as far as 6757.14% in 2015.
- SELLAS Life Sciences' Capital Expenditures stood at -$234000.0 in 2013, then jumped by 103.85% to $9000.0 in 2014, then surged by 4933.33% to $453000.0 in 2015, then plunged by 101.32% to -$6000.0 in 2016.
- Business Quant data shows SLS's Capital Expenditures at -$6000.0 in Q4 2016, $6000.0 in Q1 2016, and $453000.0 in Q4 2015.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 6.26 Mn |
| 10 | SELLAS Life Sciences | 2.62 Bn | 2.62 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2016 | 6,000.00 |
| Jun 30, 2015 | 34,000.00 |
| Mar 31, 2015 | 500,000.00 |
| Dec 31, 2014 | 3.01 Mn |
| Sep 30, 2014 | 19,000.00 |
| Jun 30, 2014 | 7,000.00 |
| Mar 31, 2014 | 22,000.00 |
| Dec 31, 2013 | 14.98 Mn |
| Sep 30, 2013 | 104,000.00 |
| Jun 30, 2011 | 13,000.00 |
| Mar 31, 2011 | 40,000.00 |
| Dec 31, 2010 | 41,000.00 |
| Sep 30, 2010 | 11,000.00 |